Featured Research

from universities, journals, and other organizations

High levels of master heat shock protein linked to poor prognosis in breast cancer patients

Date:
November 1, 2011
Source:
Whitehead Institute for Biomedical Research
Summary:
Scientists report that patients whose estrogen receptor (ER)-positive breast cancers have high levels of an ancient cellular survival factor experience poor outcomes -- including increased mortality. According to the American Cancer Society, approximately two-thirds of breast cancer patients have ER-positive tumors. HSF1 status may shed light not only on prognosis but also on how such patients might respond to specific therapies.

Whitehead Institute scientists report that patients whose estrogen receptor (ER)-positive breast cancers have high levels of the ancient cellular survival factor heat shock factor 1 (HSF1) experience poor outcomes -- including increased mortality.

According to the American Cancer Society, approximately two-thirds of breast cancer patients have ER-positive tumors. Although ER-positive breast cancers are often associated with better outcomes than other breast cancer tumor types, including those that are negative for the HER-2 receptor and so-called triple negative breast cancers (those lacking estrogen, progesterone, and HER-2 receptors), patient prognoses can still vary widely.

"If HSF1 status can help predict which of the ER-positive patients will do well with standard treatments and which ones won't, that would be really helpful," says Sandro Santagata, who is a postdoctoral researcher in Whitehead Member Susan Lindquist's lab. "In terms of understanding the biology, we think these findings are really important for reinforcing our interest in pursuing the heat shock response itself as a therapeutic target."

"HSF1's relationship to prognosis [in ER-positive patients] raises the interesting possibility for diagnostic applications -- HSF1 levels may have a role in helping determine who will have a better outcome and possibly who will have a poorer response to certain drugs," says Sandro Santagata, a postdoctoral researcher in the lab of Whitehead Member Susan Lindquist and first author of the study whose results are published online this week in the Proceedings of the National Academy of Sciences.

The heat shock response, which is controlled by transcription factors like HSF1, enables cells to withstand temperature spikes and other stressors. Crammed with distorted and abnormal proteins, cancer cells are deviants that live in a tumor's distorted landscape; a world lacking abundant nutrients and oxygen. To survive these exceptionally stressful circumstances, many cancer cells have usurped the normally beneficial heat shock response to support their existence.

To see how HSF1 levels in cancer cell nuclei are associated with the cancer's aggressiveness, Santagata examined HSF1 levels in breast cancer tissue samples from 1,841 participants in one of the largest and longest-running epidemiological studies of women's health, the Nurses' Health Study. Santagata and colleagues at the Harvard School of Public Health and University of Miami then looked at the relationship between HSF1 status and the participants' outcomes. Compared with ER-positive breast cancer patients with low levels of HSF1, those with high levels of HSF1 had a poorer outcome, including increased mortality. He also noted that invasive ER-positive tumors with elevated HSF1 levels tended to be larger and more aggressive than those with normal HSF1 levels.

Because of this strong link between HSF1 concentrations and prognosis, HSF1 testing could become a valuable part of the oncologist's toolkit.

"If HSF1 status can help predict which of the ER-positive patients will do well with standard treatments and which ones won't, that would be really helpful," says Santagata, who is also an instructor in pathology at Brigham and Women's Hospital. "In terms of understanding the biology, we think these findings are really important for reinforcing our interest in pursuing the heat shock response itself as a therapeutic target."

This research was supported by the Breast Cancer Research Foundation, National Cancer Institute, Department of Defense Congressionally Directed Medical Research Programs (DoD-CDMRP) Breast Cancer Research Program, Public Health Service, Specialized Program Of Research Excellence (SPORE) in Breast Cancer from the National Cancer Institute, Department of Health and Human Services, GlaxoSmithKline, Susan G. Komen Breast Cancer Foundation, American Cancer Society New England Division-SpinOdyssey, Marble Foundation, and V Foundation for Cancer Research.


Story Source:

The above story is based on materials provided by Whitehead Institute for Biomedical Research. The original article was written by Nicole Giese. Note: Materials may be edited for content and length.


Journal Reference:

  1. Sandro Santagata, Rong Hu, Nancy U. Lin, Marc L. Mendillo, Laura C. Collins, Susan E. Hankinson, Stuart J. Schnitt, Luke Whitesell, Rulla M. Tamimi, Susan Lindquist, and Tan A. Ince. High levels of nuclear heat-shock factor 1 (HSF1) are associated with poor prognosis in breast cancer. PNAS, 2011 DOI: 10.1073/pnas.1115031108

Cite This Page:

Whitehead Institute for Biomedical Research. "High levels of master heat shock protein linked to poor prognosis in breast cancer patients." ScienceDaily. ScienceDaily, 1 November 2011. <www.sciencedaily.com/releases/2011/10/111031154121.htm>.
Whitehead Institute for Biomedical Research. (2011, November 1). High levels of master heat shock protein linked to poor prognosis in breast cancer patients. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2011/10/111031154121.htm
Whitehead Institute for Biomedical Research. "High levels of master heat shock protein linked to poor prognosis in breast cancer patients." ScienceDaily. www.sciencedaily.com/releases/2011/10/111031154121.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com
$23.6 Billion Awarded To Widow In Smoking Lawsuit

$23.6 Billion Awarded To Widow In Smoking Lawsuit

Newsy (July 20, 2014) Cynthia Robinson claims R.J. Reynolds Tobacco Company hid the health and addiction risks of its products, leading to the death of her husband in 1996. Video provided by Newsy
Powered by NewsLook.com
Tooth Plaque Provides Insight Into Diets Of Ancient People

Tooth Plaque Provides Insight Into Diets Of Ancient People

Newsy (July 19, 2014) Research on plaque from ancient teeth shows that our prehistoric ancestor's had a detailed understanding of plants long before developing agriculture. Video provided by Newsy
Powered by NewsLook.com
Contaminated Water Kills 3 Babies in South African Town

Contaminated Water Kills 3 Babies in South African Town

AFP (July 18, 2014) Contaminated water in South Africa's northwestern town of Bloemhof kills three babies and hospitalises over 500 people. The incident highlights growing fears over water safety in South Africa. Duration: 02:22 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins